Replies to post #258910 on Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

What I don't understand is why use expressions such as inflection point or success at End of phase 2 BOM Fda meeting would help the company develop their other assets.

Because the coming deal will provide enough upfront money to start more Kevetrin and Brilacidin development. We would be doing so much more if we had funding.

Or success in OM or Pruisol would open up enormous opportunities. Why tell shareholders that without something all but signed.

Success in B-OM is opening up serious partnership discussions. We had/have at least one non-binding term sheet and multiple advanced discussions.

At some point, it is or isn't and shareholders should be informed.

You will be in informed. If we end up going out of business or fire up a massively dilutive financing plan you will know that stuff isn't good. If we sign a decent partnership deal you will know that stuff is good.

That's where we are. The end of this chapter is near. The inflection point is upon us. Only question is if the line will break up, down, or will it even keep going to the right at all?